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journal.publications.chestneBACKGROUND: Hemodynamic differentiation between pulmonary arterial hypertension
(PAH) and postcapillary pulmonary hypertension (PH) is important because treatment
options are strikingly different for the two disease subsets. Whereas patients with PAH can be
treated effectively with targeted therapies, their use in postcapillary PH is currently not
recommended. Our aim was to establish an algorithm to identify patients who are likely to
experience a signiﬁcant hemodynamic treatment response.
METHODS: We determined hemodynamic cutoffs to discriminate between idiopathic PAH
and postcapillary PH in a large database of 4,363 stable patients undergoing ﬁrst diagnostic
right and left heart catheterizations. In a second step, we performed a patient-level pooled
analysis of four randomized, placebo-controlled trials including 541 patients with PAH who
received treprostinil or placebo, to validate hemodynamic cutoffs with regard to treatment
response.
RESULTS: Receiver operating characteristic analysis identiﬁed mean pulmonary arterial wedge
pressure (mPAWP) < 12 mm Hg and diastolic pulmonary vascular pressure gradient
(DPG) $ 7 mm Hg as the best hemodynamic discriminators between idiopathic PAH and
postcapillary PH. In our treatment study, only patients with mPAWP < 12 mm Hg,
DPG > 20 mm Hg or a combination of both had a signiﬁcant placebo-corrected improve-
ment in hemodynamics.
CONCLUSIONS: mPAWP < 12 mm Hg and DPG > 20 mm Hg identify patients with PAH
who are likely to have signiﬁcant hemodynamic improvement with prostacyclin treatment.
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Pulmonary arterial hypertension (PAH) affects the
precapillary arteriolar compartment. By contrast,
postcapillary pulmonary hypertension (PH) results from
the passive hydrostatic transmission of pulmonary
vascular pressure in left heart disease (LHD). Whereas
targeted therapies may improve hemodynamics and
functional capacity in PAH, randomized controlled
trials failed to demonstrate their beneﬁcial effect in
heart failure1-3 and postcapillary PH.4,5 Therefore,
the use of PAH-targeted therapies in patients with
postcapillary PH currently is not recommended.6
Because of the difﬁcult diagnostic differentiation
between precapillary and postcapillary PH, particularly
in the presence of left ventricular diastolic dysfunction,
patients with postcapillary PH were enrolled in past and
current trials of PAH. Currently, mean pulmonary
arterial wedge pressure (mPAWP) # 15 mm Hg serves
to distinguish between precapillary and postcapillary
disease. However, the upper limit of normal mPAWP in
healthy subjects has been reported to be 11 mm Hg.7
Based on this observation, an mPAWP < 12 mm Hg
was an entry criterion in the National Institutes of
Health registry of primary PH8 and this threshold
is still recommended for the diagnosis of heart
failure with preserved ejection fraction.9 In addition,
elevated diastolic pulmonary vascular pressure
gradient (DPG) is associated with pulmonary1062 Original Researchvascular disease, right ventricular (RV) dysfunction,
and decreased survival.6,10-13
Despite treatment with targeted therapies, pulmonary
vascular resistance (PVR) remains elevated and
pulmonary arterial compliance (CPA)
14 remains low
in the vast majority of patients, with a high annual
mortality rate of PAH of 8% to 15%.15,16 Previous
studies identiﬁed baseline PVR, RV ejection fraction,17
and CPA
18 as predictors of survival in PAH. Changes in
RV afterload parameters in patients who are treated with
targeted therapies and their impact on survival have
been less well studied, and it remains unclear which
patients respond best to targeted therapies. We
hypothesized that a precapillary hemodynamic proﬁle is
characterized by an mPAWP that is lower than currently
accepted, an elevated DPG, and a beneﬁcial response to
PAH-targeted therapies.
The purposes of this study were (1) to deﬁne
hemodynamic thresholds between precapillary and
postcapillary PH with the goal of excluding patients with
left heart disease as the cause or comorbidity of PH;
(2) to identify hemodynamic predictors of treatment
response in PAH (treatment response study), and (3) to
study changes in correlates of RV afterload in patients
who are treated with targeted therapies, and their impact
on outcomes (outcome study).Materials and Methods
Retrospective Cohort
Between May 1996 and June 2006, 4,363 stable patients underwent a
ﬁrst diagnostic right heart catheterization (RHC) at the Medical
University of Vienna, a national PH referral center (Fig 1A). In
3,524 patients (81%), the procedure was combined with a left heart
catheterization. Catheterizations were performed for various
indications, mostly for suspected PH, but also before major surgical
procedures. Patients were stable, able to remain in a supine position
for the duration of the catheterization, receiving optimized diuretic
treatment, and not receiving oral anticoagulation and oxygen.
For hemodynamic assessment, a 7F Swan-Ganz catheter (Edwards
Lifesciences, Irvine, CA) was inserted using a femoral or jugular
approach. Mean pulmonary artery pressure (mPAP), mean right
atrial pressure (mRAP), RV pressure, mPAWP, and respective
oxygen saturations, including inferior and superior vena cava, were
measured. Left atrial pressure was measured transseptally when
indicated. Left ventricular end-diastolic pressure (LVEDP) was
measured with a 5F pigtail catheter (Cordis, Bridgewater, NJ). All
pressures were recorded as averages of eight time-pressure integral
derivations during several respiratory cycles.19,20 Cardiac output
(CO) was assessed by thermodilution. In the presence of systemic-
to-pulmonary shunts, the Fick method was applied. Zero reference
was at midthoracic level.21
PH was deﬁned by an mPAP $ 25 mm Hg and was classiﬁed based
on a combination of clinical, hemodynamic, and imaging data(echocardiography, ventilation-perfusion lung scintigraphy,
multidetector CT, and pulmonary angiography).22 In case of
disagreement, clinical phenotyping was allowed to overrule
hemodynamics. For example, a 70-year-old obese diabetic patient
with arterial hypertension, atrial ﬁbrillation, stable ischemic heart
disease, a normal ventilation-perfusion scan, and diastolic dysfunction
on echocardiography but with an mPAWP of 11 mm Hg would have
been classiﬁed as having postcapillary PH. A 35-year-old patient
classiﬁed as New York Heart Association functional class IV with no
cardiovascular or pulmonary comorbidities, a normal ventilation-
perfusion scan and an mPAWP of 16 mm Hg would have been
classiﬁed as having advanced idiopathic PAH (iPAH) with mPAWP
elevation as a consequence of right heart failure. As a rule, at least
three clinical risk factors for LHD were required to overrule a single
hemodynamic criterion. Patients with PAH associated with
connective tissue disease, congenital heart disease, portal
hypertension, or HIV as well as PH resulting from interstitial lung
disease (moderate to severe) and/or COPD (GOLD 3/4) and/or OSA,
and chronic thromboembolic PH, diagnosed in association with LHD,
were classiﬁed as having a combination of diagnoses (“Multiple PH”)
(Fig 1A). The Ethics Committee of the Medical University of Vienna
approved data analyses (Nos. 617/2011 and 1177/2011).
Treatment Cohort
We used deidentiﬁed individual patient data from four randomized
placebo-controlled trials (P01:03 [n ¼ 26], P01:04 [n ¼ 224], P01:05
[n ¼ 246], and Treprostinil IV for Untreated Symptomatic PAH
Trial (TRUST) [n ¼ 45]) and one open-label trial (P01:06 [n ¼ 437])[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
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Figure 1 – Patient disposition. A, Retrospective cohort. A total of 1,410 patients were classiﬁed as having postcapillary PH, 257 as having precapillary
PH, and 43 as having Multiple PH. Of these, 38 patients had iPAH. B, Treatment cohort. The cohort consisted of patients who were enrolled in
four randomized placebo-controlled trials (gray shading; P01:03 [n ¼ 26], P01:04 [n ¼ 224], P01:05 [n ¼ 246], and TRUST [n ¼ 45]) and one open-
label trial (P01:06 [n ¼ 437]) of parenteral treprostinil in PAH. aOf those 283 patients, 238 received SC treprostinil; the remaining 45 patients (who
were enrolled in TRUST) were treated with IV treprostinil. Cpc-PH ¼ combined precapillary and postcapillary PH; CTEPH ¼ chronic thromboembolic
pulmonary hypertension; iPAH ¼ idiopathic PAH; Ipc-PH ¼ isolated postcapillary PH; PAH ¼ pulmonary arterial hypertension; PH ¼ pulmonary
hypertension; RHC ¼ right heart catherization; SC ¼ subcutaneous; TRUST ¼ Treprostinil IV for Untreated Symptomatic PAH Trial.
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of treprostinil in PAH, with similar inclusion criteria and data collection
processes, as well as written informed consent.23-25 Short-term and long-
term data from 978 patients were available for survival analyses
(outcome study) (Fig 1B). RHC was performed in all patients at
baseline. Patients in the placebo-controlled trials underwent follow-up
RHC after 8 (P01:03) or 12 weeks (P01:04, P01:05, and TRUST) of
treatment (n ¼ 541; treatment response study) (Fig 1B).
Hemodynamic data were incomplete in 26 patients. Treprostinil was
administered as a continuous subcutaneous infusion, or IV in TRUST.
Patients randomized to treprostinil continued receiving treprostinil at
the same dose they were receiving at the end of the prior study, with
subsequent dose adjustments. Patients receiving placebo in previousTABLE 1 ] Retrospective Cohort: Clinical and Hemodynam
Postcapillary PH
Clinical/Hemodynamic Variable
Clinical variable
Age, mean  SD, y
Sex, No. (%)
Male
Female
BMI, mean  SD, kg/m2
Systemic hypertension, No. (%)
Stable ischemic heart disease, No. (%)
Atrial ﬁbrillation, No. (%)
Creatinine clearance < 60 mL/min, No. (%)
WHO functional class, No. (%)
I
II
III
IV
Hemodynamic variable
Heart rate, mean  SD, beats/min
Cardiac output, mean  SD, L/min
Cardiac index, mean  SD, L/min/m2
Mixed venous oxygen saturation, mean  SD (%)
Mean right atrial pressure, mean  SD, mm Hg
Pulmonary arterial systolic pressure, mean  SD, mm Hg
Pulmonary arterial diastolic pressure, mean  SD, mm Hg
Mean pulmonary arterial pressure, mean  SD, mm Hg
Mean pulmonary arterial wedge pressure, mean  SD,
mm Hg
Systemic vascular resistance, mean  SD, WU
Pulmonary vascular resistance, mean  SD, WU
Pulmonary arterial compliance, mean  SD, mL/mm Hg
Pulmonary vascular resistance-compliance time,
mean  SD, s
Transpulmonary gradient, mean  SD, mm Hg
Diastolic pulmonary vascular pressure gradient,
mean  SD, mm Hg
iPAH ¼ idiopathic pulmonary arterial hypertension; PH ¼ pulmonary hyperten
1064 Original Researchcontrolled studies and de novo patients started treprostinil at a dosage
of 1.25 ng/kg/min with increases in dosage based on PAH signs and
symptoms, and side effects. Patients were observed for a median of
15.8 months (25th and 75th percentiles at 4.1 and 28.6 months,
respectively).Hemodynamic Deﬁnitions
Transpulmonary gradient (TPG) was calculated by subtracting
mPAWP from mPAP; PVR was calculated by dividing TPG by CO
and expressed in Wood units (WU) (mm Hg  min  L-1). DPG
was calculated as the difference between diastolic pulmonary arteryic Characteristics of Patients With Precapillary and
Precapillary PH (n ¼ 257)
Postcapillary PH
(n ¼ 1,410)All (n ¼ 257) iPAH (n ¼ 38)
53.3  16.1 48.3  14.7 62.7  13.0
103 (40.9) 13 (34.2) 882 (62.6)
154 (59.1) 25 (65.8) 528 (37.4)
25.9  5.5 26.3  7.4 27.2  18.8
66 (25.7) 9 (23.7) 647 (45.9)
26 (10.1) 4 (10.5) 632 (44.8)
30 (11.7) 4 (10.5) 567 (40.2)
82 (31.9) 12 (31.8) 587 (41.6)
10 (3.4) 0 32 (2.3)
45 (17.5) 8 (21.1) 208 (14.8)
150 (58.4) 23 (60.5) 819 (58.1)
52 (20.2) 7 (18.4) 351 (24.9)
79.3  15.2 76.9  14.7 77.3  15.4
4.7  1.4 4.1  1.1 4.7  1.4
2.5  0.7 2.3  0.6 2.6  1.7
63.9  12.5 61.0  10.8 62.4  9.5
8.0  4.9 7.4  5.0 10.5  5.4
76.7  26.6 86.8  22.8 56.8  15.8
29.5  12.3 35.9  12.6 25.3  7.6
47.5  16.7 54.4  15.2 37.6  9.7
9.6  3.9 7.5  2.6 24.6  7.4
22.4  7.2 28.3  7.8 29.8  6.3
8.7  4.7 12.0  5.3 3.0  2.0
1.6  1.3 1.2  0.5 2.3  1.3
0.6  0.4 0.7  0.2 0.3  0.2
37.5  15.3 46.1  14.4 13.1  7.4
19.6  11.1 28.4  12.5 0.7  6.5
sion; WHO ¼ World Health Organization; WU ¼ Wood units.
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pressure and mPAWP.12,26 CPA was deﬁned as stroke volume divided
by pulmonary arterial pulse pressure (the difference between systolic
and diastolic pulmonary artery pressure).
Deltas (D) were calculated to assess changes between baseline and
follow-up (D ¼ value at follow-up – value at baseline) in the
treatment response study (n ¼ 541).
Statistical Analysis
Quantitative variables are described as mean and SD. Two-sample
Student t test was used to compare continuous variables between
groups. Qualitative variables are described as counts and percentages.
The potential of various hemodynamic parameters to distinguish
iPAH from postcapillary PH was assessed with receiver operating
characteristic (ROC) curves. ROC analyses were also performed
to assess interactions between changes in afterload. Cutoff values were
determined by maximizing the Youden index, which is the sum of
sensitivity and speciﬁcity – 1. The method of DeLong et al27 was usedA
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Figure 2 – Hemodynamic thresholds discriminating iPAH from isolated post
CPA, mRAP, DPG, TPG, and PVR. A, Hemodynamic parameters that are hig
Cutoffs were determined by maximizing the Youden index: mPAWP of 12 m
1.3 mL/mm Hg, and mRAP of 7 mm Hg. AUC ¼ area under the curve; CPA
pressure gradient; mPAWP ¼ mean pulmonary arterial wedge pressure; mRA
ROC ¼ receiver operating characteristic; TPG ¼ transpulmonary gradient; W
abbreviations.
journal.publications.chestnet.orgto compare areas under two ROC curves. Univariate and multivariate
Cox proportional hazards regression models were used to examine the
effects of several variables on survival. Multivariate models were
adjusted for age, World Health Organization (WHO) functional class,
6-min walk distance (6-MWD), and heart rate at baseline.
Proportionality and linearity assumptions were evaluated for
continuous variables. We added interaction terms of covariates and log
of survival time to the model to improve the model performance
when proportionality assumptions were not satisﬁed. The ﬂexible Cox
proportional hazard model using smoothing methods such as
restricted cubic spline function was implemented when the linear
functional relationship between the covariate of interest and survival
(linearity assumption) was violated. Colinearity, numerical stability,
and inﬂuence measures were also evaluated. Cox proportional hazard
models were assessed using a global goodness-of-ﬁt test and Cox-Snell
residuals. Data were analyzed with SPSS Statistics (version 21 for Mac)
and SAS (version 9.2 for Windows). All P values result from two-
sided tests, with signiﬁcance at .05.Results
Hemodynamic Discrimination Between Precapillary
and Postcapillary PH
A total of 2,957 complete datasets of the retrospective
cohort were available (Fig 1A, Table 1), 1,247 were
classiﬁed as normal (“Non-PH”, mPAP < 25 mm Hg)
and a total of 1,710 patients had PH (mPAP $ 25 mm
Hg; Fig 1A). 1,410 were classiﬁed as having postcapillary
PH (82.5%), 257 as having precapillary PH (15.0%), and
43 as having “Multiple PH” (2.5%). Of 257 patients withprecapillary PH, 38 had iPAH. There were 1,209 patients
with postcapillary PH who were classiﬁed as having
isolated postcapillary PH (DPG < 7 mm Hg) and 201
who were classiﬁed as having combined precapillary and
postcapillary PH (DPG $ 7 mm Hg).6,10
The best hemodynamic parameters for discriminating
between iPAH and isolated postcapillary PH were
mPAWP (area under the curve [AUC], 0.999)
(Fig 2A) and DPG (AUC, 0.998) (Fig 2B). For example,
a DPG $ 7 mm Hg was 100% speciﬁc for an iPAHB
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capillary PH. A, B, Receiver operating characteristic curves of mPAWP,
her in Ipc-PH. B, Hemodynamic parameters that are elevated in iPAH.
m Hg, DPG of 7 mm Hg, TPG of 22 mm Hg, PVR of 4.5 WU, CPA of
¼ pulmonary arterial compliance; DPG ¼ diastolic pulmonary vascular
P ¼ mean right atrial pressure; PVR ¼ pulmonary vascular resistance;
U ¼ Wood units. See Figure 1 legend for expansion of other
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diagnosis against an isolated postcapillary PH
diagnosis. AUCs for mPAWP and DPG were
signiﬁcantly larger than AUCs derived from TPG,
PVR, CPA, and mRAP (all P < .01). The highest
Youden index for mPAWP was at a threshold of
12 mm Hg (0.962), and for DPG at 7 mm Hg (0.968).
AUCs, sensitivities, speciﬁcities, and Youden indexes
of the different hemodynamic parameters are providedTABLE 2 ] Treatment Cohort: Baseline Clinical and Hemody
or Placebo
Clinical/Hemodynamic Variable
Clinical variable
Age, mean  SD, y
Sex, No. (%)
Male
Female
BMI, mean  SD, kg/m2a
6-MWD, mean  SD, mb
WHO functional class, No. (%)
II
III
IV
Pulmonary hypertension etiology, No.(%)c
Idiopathic pulmonary arterial hypertension
Associated pulmonary arterial hypertension
Connective tissue disease
Congenital systemic-to-pulmonary shunt
Portal hypertension
Chronic thromboembolic pulmonary hypertension
Hemodynamic variable (range)
Heart rate, mean  SD, beats/min
Cardiac output, mean  SD, L/min
Cardiac index, mean  SD, L/min/m2
Mean right atrial pressure, mean  SD, mm Hg
Pulmonary arterial systolic pressure, mean  SD, mm Hg
Pulmonary arterial diastolic pressure, mean  SD, mm Hg
Mean pulmonary arterial pressure, mean  SD, mm Hg
Mean pulmonary arterial wedge pressure, mean  SD, mm H
Systemic vascular resistance, mean  SD, WU
Pulmonary vascular resistance, mean  SD, WU
Pulmonary arterial compliance, mean  SD, mL/mm Hg
Pulmonary vascular resistance compliance time, mean  SD,
Transpulmonary gradient, mean  SD, mm Hg
Diastolic pulmonary vascular pressure gradient, mean  SD,
6-MWD ¼ 6-min walk distance; WU ¼ Wood units. See Table 1 for expansion
aBMI missing for four patients receiving treprostinil.
b6-MWD available for 283 patients in the treprostinil group.
cCause missing for two patients in the placebo group.
1066 Original Researchin e-Table 1. Similar thresholds were obtained when all
patients with PAH (n ¼ 125) and postcapillary PH
(n ¼ 1,410) were considered.
Treatment Response Study: Hemodynamic
Correlates of Afterload
Table 2 lists baseline hemodynamics and patient
characteristics of the treatment cohort (n ¼ 978).namic Characteristics of Patients Receiving Treprostinil
Placebo (n ¼ 258) Treprostinil (n ¼ 720)
43.8  14.3 45.5  15.7
60 (23.3) 179 (24.9)
198 (76.7) 541 (75.1)
26.8  6.6 26.9  10.3
322  89.2 323  86.8
31 (12.0) 102 (14.2)
205 (79.5) 553 (76.8)
22 (8.5) 65 (9.0)
158 (61.2) 355 (49.4)
100 (38.8) 314 (43.7)
50 (19.4) 129 (18.0)
50 (19.4) 142 (19.8)
0 43 (6.0)
0 49 (6.8)
244-258 472-528
82.8  15.3 82.3  13.1
3.9  1.3 4.1  1.7
2.3  0.8 2.4  0.9
10.2  6.2 10.4  5.9
95.2  23.2 93.2  23.0
40.4 13.1 40.3  14.0
60.3  15.6 59.6  16.1
g 9.4  3.6 9.6  3.5
22.9  8.7 21.8  8.7
14.6  7.4 13.8  7.2
1.0  0.5 1.1  0.7
s 0.7  0.2 0.7  0.3
50.3  15.1 49.3  15.6
mm Hg 30.5  12.5 30.0  13.5
of other abbreviation.
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Patients with a DPG # 20 mm Hg were older, heavier,
and more likely to have comorbidities associated with
LHD than were those who had a higher DPG. Patients
with an mPAWP > 12 mm Hg were heavier and more
likely to be diabetic than were those with a lower
mPAWP (e-Tables 2, 3). In 541 patients who underwent
follow-up RHC, CPA did not change from baseline,
whereas PVR (Mean [95% CI], –2.4 WU [–3.3 to –1.4])
was signiﬁcantly reduced from baseline with treprostinil
compared with placebo. Based on the hyperbolic
relationship between resistance and compliance, we
assessed the PVR threshold for a signiﬁcant change in
CPA. ROC analysis revealed that PVR had to be reduced
by at least 1 WU to achieve an increase in CPA (AUC,
0.85). Patients with an increase in CPA showed a
signiﬁcant reduction in afterload (DmPAP: –3.2 
8.6 mm Hg; DPVR: –3.0  4.8 WU), unlike patients
with a decrease in CPA (DmPAP: 1.6  7.5 mm Hg;
DPVR: 1.8  3.9 WU).Baseline Hemodynamic Predictors of Treatment
Response
To identify patients with a signiﬁcant improvement in RV
afterload, those undergoing follow-up RHC were
stratiﬁed using an mPAWP of 12 mm Hg and a DPG
of 20 mm Hg. A DPG threshold with a higher sensitivity
at 20 mm Hg (Youden index of 0.823) was used to
minimize the chances of misclassifying patients with
postcapillary PH as having precapillary PH (87% of iPAH
patients had a DPG > 20 mm Hg). Only eight patients
(1.5%) in the treatment cohort had a DPG < 7 mm Hg.
mPAWP < 12 mm Hg (n [ 362) vs mPAWP
‡ 12 mm Hg (n[ 153): Patients who were treated with
treprostinil and who had an mPAWP < 12 mm Hg
showed a signiﬁcant placebo-corrected improvement in
CO (0.4 L/min; 95% CI, 0.2-0.6), mRAP (–2.6 mm Hg;
95% CI, 3.6 to –1.5), mPAP (–3.5 mm Hg; 95% CI, –5.2
to –1.7), DPG (–3.1 mm Hg; 95% CI, –4.8 to –1.3), TPG
(–2.65 mm Hg; 95% CI, –4.5 to –0.8), PVR (–2.8 WU;
95% CI, –3.9 to –1.7), and CPA (0.1 mL/mm Hg; 95% CI,
0-0.2) (Fig 3). By contrast, patients with an mPAWP
$ 12 mm Hg improved only in CO (0.5 L/min;
95% CI, 0.2-0.8) compared with placebo. Patients
who were treated with treprostinil and had an
mPAWP < 12 mm Hg (22.9 m; 95% CI, 7.0-38.7)
and those with an mPAWP $ 12 mm Hg (34.8 m;
95% CI, 11.9-57.8) showed signiﬁcant placebo-corrected
improvement in 6-MWD. There was no difference in
the proportion of patients under treprostinil who had
$ 15% deterioration in 6-MWD with an mPAWPjournal.publications.chestnet.org< 12 mm Hg (12.8%) vs an mPAWP > 12 mm Hg
(16.3%; P ¼ .346).
DPG £ 20 mm Hg (n [ 84) vs DPG > 20 mm Hg
(n [ 431): Patients who were treated with treprostinil
and had a DPG > 20 mm Hg showed a signiﬁcant
placebo-corrected improvement in CO (0.5 L/min;
95% CI, 0.3-0.7), mRAP (–2.1 mm Hg; 95% CI, –3.2
to –1.1), mPAP (–2.4 mm Hg; 95% CI, –4.2 to –0.7),
DPG (–2.7 mm Hg; 95% CI, –4.5 to –0.9), TPG
(–2.0 mm Hg; 95% CI, –3.8 to –0.3), PVR (–2.8 WU;
95% CI, –3.9 to –1.7), and CPA (0.1 mL/mm Hg;
95% CI, 0-0.2) (Fig 3). By contrast, hemodynamics in
patients who were treated with treprostinil and had a
DPG # 20 mm Hg did not change (Fig 3) compared
with hemodynamics in those who were given a placebo.
Only patients who were treated with treprostinil and
had a DPG > 20 mm Hg showed signiﬁcant placebo-
corrected improvements in 6-MWD (26.8 m; 95% CI,
12.7-41.0). Patients who were treated with treprostinil
and had a DPG # 20 mm Hg were more likely to
experience $ 15% deterioration in 6-MWD (21.6%)
compared with those who had a DPG > 20 mm Hg
(12.3%; P ¼ .034).
mPAWP < 12 mm Hg and DPG > 20 mm Hg
(n [ 309) vs mPAWP ‡ 12 mm Hg and/or DPG
£ 20 mm Hg (n [ 206): Patients who were treated
with treprostinil and who had a combination of
mPAWP < 12 mm Hg and DPG > 20 mm Hg showed
a signiﬁcant placebo-corrected improvement in CO
(0.5 L/min; 95% CI, 0.3-0.8), mRAP (–2.9 mm Hg;
95% CI, –4.0 to –1.7), mPAP (–3.4 mm Hg; 95% CI,
–5.3 to –1.5), DPG (–3.3 mm Hg; 95 CI, –5.3 to –1.3),
TPG (–2.7 mm Hg; 95% CI, –4.7 to –0.7), PVR
(–3.2 WU; 95% CI, 4.5 to –2.0), and CPA (0.1 mL/mm Hg;
95% CI, 0-0.2) (Fig 3). By contrast, in patients who
were treated with treprostinil and had an mPAWP
$ 12 mm Hg and/or a DPG # 20 mm Hg, only CO
(0.3 L/min; 95% CI, 0-0.6) showed a signiﬁcant
placebo-corrected increase. Patients who were treated
with treprostinil and had a combination of mPAWP
< 12 mm Hg and DPG > 20 mm Hg (23.7 m; 95% CI,
6.2-41.1) and those who had an mPAWP $ 12 mm Hg
and/or a DPG # 20 mm Hg (30.3 m; 95% CI,
10.5-50.1) showed signiﬁcant placebo-corrected
improvements in 6-MWD. There was no difference
in the proportion of patients who were treated with
treprostinil who had $ 15% deterioration in 6-MWD
(mPAWP < 12 mm Hg and DPG > 20 mm Hg:
12.4% vs mPAWP $ 12 mm Hg and/or DPG
# 20 mm Hg: 15.9%; P ¼ .310).1067
Figure 3 – Hemodynamic changes from
baseline. Placebo-corrected changes from
baseline in mRAP (A), PVR (B) and
CPA (C). All values were normally
distributed. P values are results of
independent-sample t tests between
placebo and treprostinil. See Figure 2
legend for expansion of abbreviations.
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Lung Transplantation
Baseline Predictors: Univariate ﬂexible hazard ratio
analysis of various hemodynamic parameters at baseline
identiﬁedmRAP and PVR as predictors of survival/freedom1068 Original Researchof lung transplantation (bothP< .001).After adjustment for
baseline age,WHO functional class, 6-MWD, and heart rate
in a multivariate ﬂexible hazard model, mRAP (P ¼ .01)
and PVR (P < .001) remained signiﬁcant predictors of
survival/freedom of lung transplantation (Fig 4A, 4B).[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
On-Treatment Predictors: Univariate analysis of
changes in hemodynamics from baseline to follow-up
revealed that only DmRAP (P ¼ .003) was an on-
treatment predictor of survival/freedom of lung
transplantation whereas DPVR showed only a statistical
trend (P ¼ .063). In the multivariate model, DmRAP
(P ¼ .017) and DPVR (P ¼ .045) predicted survival/
freedom of lung transplantation.
At follow-up, mRAP and PVR (both P < .001) were
signiﬁcant univariate predictors of outcome. After
adjusting for age, WHO functional class, 6-MWD, and0 5
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Figure 4 – Hemodynamic predictors of survival/freedom of lung transplantatio
at baseline (A, B) and follow-up (C, D). Analyses were adjusted for age, Wor
rate. Dashed blue lines mark CIs of the hazard functions. See Figure 2 legen
journal.publications.chestnet.orgheart rate at baseline, mRAP and PVR (both P < .001)
remained signiﬁcant predictors of survival/freedom of
lung transplantation (Fig 4C, 4D).Discussion
Our data show that: (1) an mPAWP < 12 mm Hg
and a DPG $ 7 mm Hg best discriminate between
iPAH and postcapillary PH; (2) patients with an
mPAWP < 12 mm Hg combined with a DPG
> 20 mm Hg are likely to have a signiﬁcant response to
PAH-targeted therapy; (3) to increase CPA, a minimal0
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1069
reduction in PVR by 1 WU is required; and (4) mRAP
and PVR are baseline and on-treatment independent
predictors of long-term survival/freedom of lung
transplantation. Although a deterioration in 6-MWD
was associated with poor prognosis in a recent REVEAL
(Registry to Evaluate Early and Long-Term Pulmonary
Arterial Hypertension Disease Management registry)
subanalysis,28 neither an absolute nor a relative change
in 6-MWD was correlated with survival in other
studies.29-32 Therefore, we used survival as the best
measure of clinical beneﬁt in our study.
We determined hemodynamic cutoffs to differentiate
between iPAH and postcapillary PH (Fig 2) in a large
contemporary database of a national referral and
tertiary care center dedicated to the science andmPAP
mPAWP
mPAWP ≥ 12 mm Hg
DPG < 7 mm Hg
Isolated postcapillary PH
DPG ≥ 7 mm Hg
Combined pre- and post-
capillary PH
1050
DPG 7-20 m
Response to pro
treatment un
DPG < 7 mm Hg
Response to prostacyclin
treatment unlikely
Diastolic pulmonary vascular pre
con
DPG
Pulmonary hype
(mPAP ≥ 25 m
Passive hydrostatic
pulmonary pressure elevation
Figure 5 – Hypothetical hemodynamic algorithm for the identiﬁcation of PA
treatment response. Because of the retrospective nature of our study, prospec
fraction. See Figure 1 and 2 legends for expansion of other abbreviations.
1070 Original Researchmanagement of pulmonary vascular disease since
1980.33 In principle, we conﬁrmed the proposal of Naeije
et al.12 mPAWP < 12 mm Hg had a sensitivity of
99.4% and speciﬁcity of 96.8% to diagnose iPAH. We
relied on mPAWP as a mean across the respiratory cycle
rather than on end-expiratory values. Although some
data suggest that patients with precapillary PH may be
mislabeled as having PH-LHD if measurements are
limited to end-expiratory pressures,19 the practice of
averaging mPAWP over the respiratory cycle to estimate
LVEDP has also been challenged.34 End-expiratory
mPAWP was almost equal to end-expiratory LVEDP,
whereas the averaged mPAWP underestimated end-
expiratory LVEDP.34 However, those authors failed to
compare averaged mPAWPs with averaged LVEDPs and
did not consider that there is a physiological gradientmPAWP < 12 mm Hg
15 20 25
m Hg
stacyclin
likely
DPG > 20 mm Hg
Response to prostacyclin
treatment likely
ssure gradient (mm Hg)
DPG < 7 mm Hg
Systemic hypotension/HFpEF
sider exercise/fluid challenge/MRI
DPG ≥ 7 mm Hg
Precapillary PH
DPG
rtension
m Hg)
Pulmonary vascular
disease
H patients who are likely to experience a signiﬁcant hemodynamic
tive validation is needed. HFpEF ¼ heart failure with preserved ejection
[ 1 4 9 # 4 CHES T A P R I L 2 0 1 6 ]
of 3 mm Hg between mPAWP and LVEDP.35 As
proposed in our algorithm (Fig 5), exercise testing and
ﬂuid challenge might be additional tools to unmask
LHD. In the 3,128-patient multicenter, US-based,
observational REVEAL registry of patients who have
received a diagnosis of PAH,36 patients with an
mPAWP of 16-18 mm Hg had outcomes similar to
those of patients with an mPAWP # 15 mm Hg; yet,
when mPAWP was > 19 mm Hg in subsequent
assessments, prognosis was signiﬁcantly worse. These
data document the high rate of contamination of a
contemporary PAH cohort with postcapillary PH,
and although thresholds were different, a signal of
“higher mPAWP begets worse prognosis with PAH
treatments” is reproduced.
We also identiﬁed DPG $ 7 mm Hg as a predictor
of iPAH with a sensitivity of 97.1% and speciﬁcity
of 92.1%. The recent assertion that DPG is limited
in clinical usefulness is based on two retrospective
database analyses that were signiﬁcantly limited by the
characteristics of patients.37,38 Whereas the ﬁrst
study was based on a population of patients with
cardiac transplants,37 the latter analyzed patients with
(sub)acute heart failure,38,39 all of which signiﬁcantly
differ from the original prognostic study of DPG.10,13
Patients in the treatment cohort with an mPAWP
< 12 mm Hg or DPG > 20 mm Hg, or a combination
of both experienced signiﬁcant placebo-corrected
improvement in RV afterload (Fig 3) with treprostinil.
The reduction in PVR was similar to that in the recent
SERAPHIN (Study with an Endothelin Receptor
Antagonist in Pulmonary Arterial Hypertension to
Improve Clinical Outcome) trial,40 in which macitentan
signiﬁcantly delayed a combined morbidity and mortality
end point. By contrast, in treprostinil-treated patients
who had an mPAWP $ 12 mm Hg and/or a DPG
# 20 mm Hg, only CO improved relative to placebo,
as in randomized controlled trials of PAH-targeted
therapies in heart failure1-3 and PH-LHD, which failed
to meet their primary end points.4,5 A single-center
study in patients with PH-LHD and a mean DPG of
7.1 mm Hg in the placebo group and 9.6 mm Hg in the
sildenaﬁl-treated group resulted in a favorable effect on
hemodynamics.41journal.publications.chestnet.orgCPA reﬂects the pulsatile load of the RV and has been
shown to be of greater prognostic importance than
PVR in patients with iPAH.18 However, CPA did not
predict survival/freedom of lung transplantation in our
study neither at baseline nor under treatment, and CPA
was lower (treprostinil: 1.1  0.7 mm Hg/mL; placebo:
1  0.5 mm Hg/mL) than in the patients with iPAH in
the study by Mahapatra et al18 (1.43  0.73 mL/mm Hg).
Mahapatra et al18 performed a 4-year follow-up of
104 patients with iPAH. In the univariate Cox
proportional hazard model, CPA was the strongest
predictor of survival, and in the successive bivariate
analysis CPA was the sole independent predictor of
mortality. In contrast to our study, those authors were not
able to perform a multivariate analysis because there were
only 21 deaths, probably because the sample size was
too small. Based on a much larger population (n ¼ 978),
we performed a survival analysis using univariate and
multivariate ﬂexible hazard ratio functions. The use
of cubic spline functions in these models allows
investigation of nonlinear effects of continuous covariates
and ﬂexible assessment of time-by-covariate interactions.
We found that mRAP and PVR at baseline and follow-up,
as well as their change from baseline (D) are predictors
of outcome. However, follow-up was shorter in our
study compared with that of Mahapatra et al18 (15.8
vs 48 months, respectively) and our cohort was a
population with mixed PAH (53% iPAH vs 100% iPAH,
respectively).
Limitations
Treprostinil was the only PAH-targeted therapy in our
study. Data for 49 patients with inoperable chronic
thromboembolic PH were considered only for survival
analyses (Table 2).
Conclusion
We propose a hemodynamic algorithm (Fig 5), using
mPAWPandDPGin sequence, to identify patientswho are
likely to improve with prostacyclin treatment, presumably
those with classical pulmonary arteriopathy. In a next step,
the algorithm needs to be validated to ensure applicability
for otherPAH-targeted therapies.Ourdata substantiate the
value of baseline and on-treatment hemodynamics for the
clinical follow-up of patients with PAH.1071
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